John Renger, Chief Scientific Officer at Cerevel Therapeutics Holdings, Inc. (CERE), sold 45,000 shares at $34.65 ($1.6M) on 2022-04-13, disclosed to the SEC on 2022-04-15.
Open-market sale of $1.6M CERE by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| CERE | SELL | 2022-10-06 | $750K | — | Filing → |
| CERE | SELL | 2022-08-12 | $4.5M | — | Filing → |
| CERE | SELL | 2022-08-09 | $1.0M | — | Filing → |